AKT1 and melanoma: In addition, 4% of melanomas resistant to BRAF inhibitors showed mutations in Akt, Phosphatase and Tensin Homolog (PTEN), and Phosphoinositol-3-Kinase (PI3K), along with other regulatory genes of the PI3K–Akt pathway associated with the development of drug resistance [11].